Wet-AMD Pipeline Outlook Report 2025: Emerging Therapies, Clinical Developments, and Drug Insights by DelveInsight

DelveInsight's "Wet-AMD Pipeline Insight 2025" report provides comprehensive insights about 60+ companies and 75+ pipeline drugs in the Wet-AMD pipeline landscape. It covers the Wet-AMD Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Wet-AMD Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Wet-AMD Pipeline? Click here to explore the therapies and trials making headlines @ Wet-AMD Pipeline Outlook Report [https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Wet-AMD Pipeline Report

* On 03 October 2025, EyePoint Pharmaceuticals Inc . conducted a 2-year Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD.
* On 02 October 2025, Adverum Biotechnologies Inc . announced a Phase 3 study in a broad participant population (treatment-naive and treatment-experienced) with neovascular (wet) age-related macular degeneration (nAMD). The study will evaluate a single intravitreal (IVT) injection of Ixo-vec compared to an active comparator. The primary endpoint of this study is the mean change in best corrected visual acuity (BCVA) of Ixo-vec compared to an active comparator measured at an average of Weeks 52 and 56.
* DelveInsight's Wet-AMD Pipeline report depicts a robust space with 60+ active players working to develop 75+ pipeline therapies for Wet-AMD treatment.
* The leading Wet-AMD Companies such as Sylentis, Molecular Partners, Sam Chun Dang Pharm, Generium, Alvotech, Adverum Biotechnologies, EyePoint Pharmaceuticals, 4D Molecular Therapeutics, OliX Pharmaceuticals, Kyowa Kirin, Exonate and others.
* Promising Wet-AMD Therapies such as NT-101 0.05 mM, AVT06, RGX-314, ABP 938, Aflibercept, HX9428 tablet, FT-003, Ranibizumab, Tarcocimab Tedromer, LFG316 and others.

Want to know which companies are leading innovation in Wet-AMD? Dive into the full pipeline insights @ Wet-AMD Clinical Trials Assessment [https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Wet-AMD Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Wet-AMD Pipeline Report also highlights the unmet needs with respect to the Wet-AMD.

Wet-AMD Overview

Wet Age-related Macular Degeneration (AMD) is a chronic eye disease that affects the macula, the central part of the retina responsible for sharp, detailed vision. It is a more severe form of AMD compared to the dry type and progresses rapidly, leading to significant vision loss if untreated. Wet AMD occurs when abnormal blood vessels grow under the macula, leaking blood or fluid, which disrupts retinal function and causes scarring. This condition primarily affects older adults, usually over the age of 50, and is a leading cause of central vision loss in this age group.

Wet-AMD Emerging Drugs Profile

* RGX-314: REGENXBIO

RGX-314 is a one-time subretinal treatment that includes the NAV AAV8 vector containing a gene encoding for a monoclonal antibody fragment. The expressed protein is designed to neutralize vascular endothelial growth factor (VEGF) activity, modifying the pathway for the formation of new leaky blood vessels and retinal fluid accumulation. RGX-314 is being developed as a potentially one-time treatment for wet AMD, diabetic retinopathy, and other additional chronic retinal conditions treated with anti-VEGF. REGENXBIO is advancing research in two separate routes of administration of RGX-314 to the eye, through a standardized subretinal delivery procedure as well as delivery to the suprachoroidal space. Currently, the drug is in the Phase III stage of its development for the treatment of Wet Age-Related Macular Degeneration (AMD).

* CLS-AX: Clearside Biomedical

CLSAX is a proprietary axitinib injectable suspension delivered via Clearside's suprachoroidal space (SCS) Microinjector Registered , designed as a long-acting treatment for wet age-related macular degeneration (wet AMD). It's a potent, panVEGF tyrosine kinase inhibitor (TKI) that offers targeted, durable delivery behind the retina, potentially reducing injection frequency while maintaining stable visual acuity. CLSAX has demonstrated positive safety and efficacy in Phase IIb (ODYSSEY) results and is currently being advanced toward a Phase III development program

* SYL1801: Sylentis

SYL1801 is a small interfering RNA (siRNA) in the non-clinical research phase. This siRNA, by means of mechanism of action based on RNA interference (RNAi), inhibits the synthesis of NRARP (Notch-regulated ankyrin repeat-containing protein). NRARP is directly involved in the pathophysiology of choroidal neovascularization, i.e. the abnormal formation of new vessels from the choroid into the retina. It is a common hallmark of several retinal diseases such as age-related macular degeneration (AMD) or diabetic retinopathy (DR). During angiogenesis (new vessel formation), NRARP integrates the Notch and Wnt signaling pathways by controlling stalk cell proliferation to stabilize new endothelial cell connections . Currently the drug in in Phase II stage of its treatment of Wet Age-Related Macular Degeneration (Wet-AMD).

* IBI 333: Innovent Biologics

IBI333 is an investigational bispecific fusion protein developed by Innovent Biologics targeting both VEGFA and VEGFC. It's currently in Phase I trials (for neovascular agerelated macular degeneration), where it is delivered via intravitreal injection to block dual angiogenic pathways and potentially overcome resistance seen with VEGFA monotherapy. Currently the drug in in Phase I stage of its treatment of Wet Age-Related Macular Degeneration (Wet-AMD).

If you're tracking ongoing Wet-AMD Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Wet-AMD Treatment Drugs [https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Wet-AMD Pipeline report provides insights into:-

* The report provides detailed insights about companies that are developing therapies for the treatment of Wet-AMD with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Wet-AMD Treatment.
* Wet-AMD Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Wet-AMD Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Wet-AMD market.

Wet-AMD Companies

Sylentis, Molecular Partners, Sam Chun Dang Pharm, Generium, Alvotech, Adverum Biotechnologies, EyePoint Pharmaceuticals, 4D Molecular Therapeutics, OliX Pharmaceuticals, Kyowa Kirin, Exonate and others.

Wet-AMD Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

* Intravenous
* Subcutaneous
* Oral
* Intramuscular

Wet-AMD Products have been categorized under various Molecule types such as,

* Monoclonal antibody
* Small molecule
* Peptide

From emerging drug candidates to competitive intelligence, the Wet-AMD Pipeline Report covers it all - check it out now @ Wet-AMD Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Wet-AMD Pipeline Report

* Coverage- Global
* Wet-AMD Companies- Sylentis, Molecular Partners, Sam Chun Dang Pharm, Generium, Alvotech, Adverum Biotechnologies, EyePoint Pharmaceuticals, 4D Molecular Therapeutics, OliX Pharmaceuticals, Kyowa Kirin, Exonate and others.
* Wet-AMD Therapies- NT-101 0.05 mM, AVT06, RGX-314, ABP 938, Aflibercept, HX9428 tablet, FT-003, Ranibizumab, Tarcocimab Tedromer, LFG316 and others.
* Wet-AMD Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Wet-AMD Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research - discover what's next for the Wet-AMD Treatment landscape in this detailed analysis @ Wet-AMD Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Wet Age-Related Macular Degeneration (Wet-AMD): Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Wet Age-Related Macular Degeneration (Wet-AMD)- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* RGX-314: REGENXBIO
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* SYL1801: Sylentis
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* IBI 333: Innovent Biologics
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Wet Age-Related Macular Degeneration (Wet-AMD) Key Companies
* Wet Age-Related Macular Degeneration (Wet-AMD) Key Products
* Wet Age-Related Macular Degeneration (Wet-AMD)- Unmet Needs
* Wet Age-Related Macular Degeneration (Wet-AMD)- Market Drivers and Barriers
* Wet Age-Related Macular Degeneration (Wet-AMD)- Future Perspectives and Conclusion
* Wet Age-Related Macular Degeneration (Wet-AMD) Analyst Views
* Wet Age-Related Macular Degeneration (Wet-AMD) Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=wetamd-pipeline-outlook-report-2025-emerging-therapies-clinical-developments-and-drug-insights-by-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.